Zucenka A, Pileckyte R, Trociukas I, et al. - Researchers analyzed results of relapsed/refractory acute myeloid leukemia patients (n = 28) who were heavily pretreated (median 3 (2‐6) treatment lines, sixteen (57%) allotransplanted) and who had failed salvage venetoclax‐based therapies, in this retrospective study. Different post‐venetoclax salvage therapies were administered to 22 patients (79%), with the overall response rate of 23% (complete remission + morphological leukemia‐free state). The rest of the 6 patients were not treated with any further salvage therapy mainly because of poor general condition. For all patients, a median overall survival of 3.9 months was reported (4.3 for those treated with post‐venetoclax salvage vs 1.3 months managed with palliative care alone). Findings although revealed poor remission rate as well as survival of patients failing venetoclax, a response to cautious intensification of chemotherapy with venetoclax may still be seen in a small proportion of these R/R AML patients.